Core Viewpoint - Reliance Global Group, Inc. reported improved financial results for Q1 2025, highlighting organic revenue growth, reduced net loss, and increased AEBITDA, positioning the company for long-term growth and enhanced profitability [2][5]. Financial Performance - Commission income revenue increased by $153,782, or 4%, to $4,236,220 in Q1 2025 from $4,082,438 in Q1 2024, reflecting organic growth in insurance distribution channels [5]. - Commission expense rose by $192,885, or 15%, to $1,469,427 in Q1 2025 compared to $1,276,542 in Q1 2024, due to higher payouts to agents [5]. - Salaries and wages increased by $398,175, or 22%, to $2,229,837 in Q1 2025 from $1,831,662 in Q1 2024, primarily due to $540,015 in non-cash equity awards [5]. - General and administrative expenses increased by $141,388 to $1,516,228 in Q1 2025 from $1,374,890 in Q1 2024, mainly due to $484,970 of non-cash equity pay [5]. - Net loss decreased by $3,609,781, or 68%, to $1,736,882 in Q1 2025 from $5,346,663 in Q1 2024, driven by the elimination of impairment charges [5]. - Adjusted EBITDA (AEBITDA) increased by $219,061, or 297%, to a gain of $145,407 in Q1 2025 compared to a loss of ($73,654) in Q1 2024, indicating a trend toward increased profitability [5][14]. Strategic Initiatives - The company is focused on completing the Spetner acquisition, which is expected to enhance its insurance capabilities and strengthen its market position [2]. - The launch of RELI Auto Leasing allows agency partners to offer vehicle leasing services, enhancing client relationships and creating a new revenue stream [2]. - Continued adoption of advanced InsurTech solutions is transforming the agent experience through AI-driven automation and improved underwriting precision [2].

QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March 31, 2025 ...

SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following ...

Company to Further Strengthen Financial Position, Improve Operations, and Expand Technology Capabilities to Drive Long-Term Growth as Part of Strategic TransformationGross Revenue: Quarterly gross revenue of $9.2 million, representing a 6% decrease from $9.8 million in 2024.Improved Adjusted EBITDA: Substantially narrowed Adjusted EBITDA loss from $9.4 million in Q1 2024 to $7.4 million in Q1 2025, underscoring enhanced operational efficiency. COLUMBIA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Rekor Systems, I ...

MINNEAPOLIS, May 14, 2025 (GLOBE NEWSWIRE) -- Nortech Systems Incorporated (Nasdaq: NSYS) (“Nortech” or the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, industrial and aerospace & defense markets, reported financial results for the first quarter ended March 31, 2025. 2025 Q1 Highlights: ●Net sales of $26.9 million ●Net loss of ($1.3) million, or ($0.48) per diluted share ●Adju ...

Beijing, May 14, 2025 (GLOBE NEWSWIRE) -- AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today announced that the Company’s board of directors approved on May 9, 2025 that the ordinary shares of the Company be consolidated on a 50 for 1 ratio. The effective date is scheduled to be June 3, 2025, subject to the Company's satisfaction of Nasdaq Operations no ...

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ...

Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter en ...

Core Insights - STRATA Skin Sciences, Inc. reported a modest revenue increase of 1% year-over-year for Q1 2025, totaling $6.8 million, with gross margins improving significantly by nearly 800 basis points to 53.5% [6][10][24] - The company has successfully executed its direct-to-consumer strategy, resulting in a 32% increase in unique psoriasis patients and a 128% increase in unique acne patients compared to the prior year [4] - International revenue grew by 8% in Q1 2025, contributing to 36% of total revenue, and is expected to continue growing as global tariff uncertainties resolve [5] Financial Performance - Revenue for Q1 2025 was $6.8 million, a 1% increase from Q1 2024, with global recurring revenue at $4.7 million and equipment revenue at $2.1 million, both up approximately 1% [6][10] - Gross profit for Q1 2025 was $3.6 million, representing 53.5% of revenue, compared to $3.1 million or 45.6% of revenue in Q1 2024 [6][24] - Total operating expenses decreased by 5% to $5.7 million, with significant reductions in engineering and product development expenses by 60% [7][24] Loss and Cash Position - The net loss for Q1 2025 was $2.4 million, or a loss per share of $0.58, an improvement from a net loss of $3.4 million or $0.96 per share in Q1 2024 [7][24] - Cash, cash equivalents, and restricted cash at the end of Q1 2025 were $7.8 million, down from $8.6 million at the beginning of the period [8][26] Strategic Developments - The company is focused on enhancing its direct-to-consumer marketing efforts and building a strong franchise in dermatology and aesthetics [20] - STRATA's partnership program offers innovative treatment technologies with a fee-per-treatment cost structure, which is expected to drive further growth [19][18]

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially fir ...